Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.35 |
| ▸ | IKBKB | O14920 | 3/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ILK | Q13418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505525 | 0.81 | ITK (0.43) | ITKKDM4EGAA | |
| SCHEMBL6506696 | 0.75 | ITK (0.56) | ITKKDM4EIRAK4HTTSMN1; SMN2 | |
| SCHEMBL6500409 | 0.74 | ITK (0.55) | ITKKDM4EGAAIRAK4HTT | |
| SCHEMBL6501912 | 0.73 | ITK (0.52) | ITKIRAK4PARP1 | |
| SCHEMBL6505234 | 0.69 | ITK (0.49) | ITKKDM4EGAAIRAK4IKBKB | |
| SCHEMBL6502017 | 0.68 | ITK (0.52) | ITKKDM4EGAAIRAK4TP53 | |
| SCHEMBL6497388 | 0.68 | KDM4E (0.53) | ITKKDM4EGAAIRAK4IKBKB | |
| SCHEMBL6503646 | 0.68 | ITK (0.51) | ITKKDM4EIRAK4SMN1; SMN2 | |
| SCHEMBL6470432 | 0.68 | SMN1; SMN2 (0.51) | ITKKDM4EGAAIRAK4HTT | |
| SCHEMBL6470657 | 0.68 | ITK (0.48) | ITKKDM4EGAAIRAK4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | ITK 4236/4885PARP14 1320/4885KDM4E 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.